AUGUST BDI-40 UP 7.1%: BENITEC UP 90%, HEARTWARE 80%
September 6th 2009 21:25
Biotech Daily
Tuesday September 1, 2009
Daily news on ASX-listed biotechnology companies
Tuesday September 1, 2009
Daily news on ASX-listed biotechnology companies
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
BIOTECH DAILY’S TOP 40 INDEX
Biotech Daily’s Top 20 and Top 40 Indices continue to outperform the S&P ASX 200, with the BDI-40 up 7.1 percent in August compared to the ASX 200 up 5.5 percent.
The striking difference is that over the 12 months to August 31, 2009, the BDI-20 was up 34.1 percent, the BDI-40 rose 27.0 percent while the ASX 200 was still 12.8 percent below the same point in the previous year. Biotechs have more than recovered, while Australia’s largest 200 companies have not.
For the month of August, 22 companies were up, 15 fell and three were unchanged.
Benitec was technically best from a low base, up 90 percent to a market capitalization of $19 million, but the most significant rise was Heartware’s 80.4 percent jump from the July 31, 2009 close following the failed Thoratec merger to last night’s $368 million which includes the $US66 million raising and its escrowed shares, not counted in data provided by the ASX.
Also from a low base, Optiscan was up 60 percent for the month to $8 million, followed by Cytopia (50%), Phylogica (45.5%), Compumedics (38.1%) and Starpharma (32.9%). Antisense, Bone, Genera, Prana, Psivida, Tissue Therapies and Universal Biosensors were up by more than 20 percent.
Tyrian led the falls down 37.5 percent to $5 million, followed by Labtech (22.2%), Mesoblast (20.7%), Viralytics (20%) and Cathrx (17.4%).
The three Big Caps of Cochlear, CSL and Resmed, which are not included in the BDI-20 and BDI-40, recovered 6.1 percent in August but were down 15.9 percent for the year, mostly due to CSL’s tumble in March 2009. Resmed was up 12.5 percent in August, CSL rose 5.7 percent, with Cochlear up 1.1 percent
Biotech companies have raised more than $256 million since January this year and more than $410 million since August 30, 2008, not including significant institutional raisings.
Biotech Daily Top 40 ($m) v S&P ASX 200 2008-‘09
Subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 36 |
| Vote |
Add To: 
subscribe to this blog